Latest Data & Signals Issued

Signal Type Signal Value Data
Score -4.374 13 days ( 14.95 % )
Last Price $2.11 7.65 %
High/ Low $2.00 - $2.14 2.99%
Chg 7 Days -3.22 % $2.18 $2.11
Chg 30 Days -22.43 % $2.72 $2.11
Chg 12 mos -75.33 % $8.55 $2.11
Trend - 3 mos -4.05 % Width: 67.47 %
Trend - 12 mos -54.38 % Width: 298.19 %
Pred. range - 3 mos $1.84 - $3.08 -12.89 % - 45.89 %
Pred. range - 12 mos $0.84 - $3.36 -60.00 % - 59.28 %
Short MA avg 3 mos Buy 2024-03-27 - 2 days
Long MA avg 3 mos Sell 2024-03-11 - 14 days
Short/Long MA avg 3 mos Sell 2024-03-13 - 12 days
Short MA avg 12 mos Buy 2024-03-07 - 16 days
Long MA avg 12 mos Sell 2024-01-11 - 54 days
Short/Long MA avg 12 mos Sell 2024-01-11 - 54 days
Pivot Short Buy 2024-03-26 - 3 days
Bollinger Buy 2023-06-27 - 191 days
MACD Sell No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-... CYCC Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT